Decoding Neurological Disease. Building Medicines.

CELLTIUM is developing precision therapies for CMT1A and related neurological disorders. By combining deep disease biology with the proprietary PRECISION™ platform, we are advancing a translationally driven approach to drug discovery.

A New Model for Neurotherapeutics
We are integrating disease biology, quantitative phenotyping, and AI into a single translational framework — from novel target identification to lead optimization — to build first‑in‑class medicines for underserved neurological diseases.

Targeting the Root Cause of CMT1A
We are advancing a portfolio of mechanistically distinct small-molecule therapies for CMT1A, the most common inherited peripheral neuropathy, with a focus on core disease mechanisms and peripheral nerve function.

Partner With Us
We welcome strategic collaborations with pharmaceutical companies, research institutions, and investors for co‑development, licensing, and investment — to accelerate CMT1A therapeutics and expand the PRECISION™ platform.

Interested in Our CMT1A Program?
MEET US AT

June 22–25 | San Diego

April 28–30 | Seoul

A New Model for Neurotherapeutics We are integrating disease biology, quantitative phenotyping, and AI into a single translational framework — from novel target identification to lead optimization — to build first‑in‑class medicines for underserved neurological diseases.

Targeting the Root Cause of CMT1A We are advancing a portfolio of mechanistically distinct small-molecule therapies for CMT1A, the most common inherited peripheral neuropathy, with a focus on core disease mechanisms and peripheral nerve function.

Interested in Our CMT1A Program? MEET US AT

A New Model for Neurotherapeutics
We are integrating disease biology, quantitative phenotyping, and AI into a single translational framework — from novel target identification to lead optimization — to build first‑in‑class medicines for underserved neurological diseases.

Targeting the Root Cause of CMT1A
We are advancing a portfolio of mechanistically distinct small-molecule therapies for CMT1A, the most common inherited peripheral neuropathy, with a focus on core disease mechanisms and peripheral nerve function.

Interested in Our CMT1A Program?
MEET US AT